In vitro synergistic/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia.
Synergy testing of levofloxacin and meropenem by Etest and time-kill assay (TKA) was performed against 30 genetically unique clinical Stenotrophomonas maltophilia isolates. Synergy was demonstrated in 18/30 (60%) isolates by Etest and in 13/30 (43%) by TKA; the remaining isolates were indifferent. Methods showed agreement for 25/30 (83%) of isolates.
Pankey
George A
GA
Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA 70121, USA. gpankey@ochsner.org
Ashcraft
Deborah S
DS
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D064704:Levofloxacin; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D015242:Ofloxacin / Q000494:pharmacology*; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D013845:Thienamycins; D064704:Levofloxacin; D015242:Ofloxacin; D000077731:Meropenem